News for Neurocrine Biosciences, Inc. (NBIX)

LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. ( VYGR), a biotechnology company dedicated to leveraging genetics to treat neur

Voyager Therapeutics (VYGR) will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference. The on-demand webcast will be available

Summary Neurocrine Biosciences Inc (NBIX) announced on June 9, 2025, the appointment of Lewis Choi as Chief Information Officer. With 25 years of experience in

Neurocrine Biosciences (NBIX) has announced that Lewis Choi will take on the role of Chief Information Officer, starting on June 9. Choi brings a wealth of expe

In the latest analyst update, RBC Capital has reiterated its "Outperform" rating for Neurocrine Biosciences (NBIX). This evaluation continues to reflect the fir

Neurocrine Biosciences (NBIX) has revealed promising outcomes from their Phase 4 KINECT-PRO open-label study, which highlights significant and persistent enhanc

After a rocky start to the spring, Wall Street came roaring back in May. President Trump’s softened tariff stance reignited demand for risk assets, triggering the market’s biggest monthly rally since November 2023. The S&P 500 rose ~6%, nudging back into positive territory for the year. Encouraged by this rebound, John Stoltzfus, chief investment strategist at Oppenheimer, has taken the measure of the markets and holds a positive outlook for the near- to mid-term. “The effects of the stock marke

SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. ( FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of in

On May 27, 2025, Kevin Gorman, a Director at Neurocrine Biosciences Inc (NBIX), sold 9,613 shares of the company. Following this transaction, the insider now ow

Neurocrine Biosciences, Inc.

We recently published a list of 15 Small-Cap Healthcare Stocks Hedge Funds Are Buying. In this article, we are going to take a look at where Neurocrine Biosciences, Inc.

U.S. stock futures decline as investors anxiously anticipate the Federal Reserve's upcoming decision.

”“ Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following

U.S. stocks were lower, with the Nasdaq Composite falling over 1% on Tuesday. Shares of FARO Technologies, Inc. FARO rose sharply during Tuesday's session afte...

Neurocrine Biosciences Inc (NBIX) exhibits a robust product portfolio with FDA-approved treatments for various neurological and endocrine disorders.Despite inc

Neurocrine Biosciences (NBIX) stock surged 13% post Q1 earnings, beating forecasts. The company's sales projection for Ingrezza remains solid at $2.5B-$

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2025 Results Conference Call May 5, 2025 4:30 PM ETCompany ParticipantsTodd Tushla - Vice President of...

PR NewswireSAN DIEGO, May 5, 2025 INGREZZA® (valbenazine) First-Quarter 2025 Net Product Sales of $545 Million and Reaffirms 2025 Net Product Sales Guidan

Revenue: $572.6 million, surpassing the estimated $559.33 million.Net Product Sales: INGREZZA achieved $545 million, marking an 8% increase year-over-year.EPS: